Claims for Patent: 9,504,236

Summary for Patent: 9,504,236

Title:	Animal models and therapeutic molecules
Abstract:	The invention pertains to a transgenic non-human mammal which contains a chimeric immunoglobulin locus containing human variable region gene segments at an endogenous Ig locus operatively linked to non-human mammalian constant region genes, and methods to produce chimeric antibodies therefrom.
Inventor(s):	Bradley; Allan (Cambridge, GB), Lee; E-Chiang (Cambridge, GB), Liang; Qi (Cambridge, GB), Wang; Wei (Cambridge, GB)
Assignee:	Kymab Limited (Cambridge, GB)
Application Number:	14/935,010
Patent Claims:	1. A transgenic mouse having a genome with homozygous immunoglobulin heavy chain (IgH) locus, wherein said homozygous IgH locus comprises unrearranged human immunoglobulin heavy chain (IgH) variable region (VH) DNA comprising one or more human IgH V gene segments, one or more human D gene segments, one or more human JH gene segments and human intronic DNA contiguous with mouse intronic DNA at an endogenous IgH locus upstream of an enhancer and a constant (C) region comprising an endogenous CH gene segment, wherein said C region comprises mouse C.mu. and said human variable region gene segments are operably linked to said C region to permit rearrangement and expression of IgM heavy chain polypeptide comprising a human variable region and a mouse .mu. constant region, wherein in said transgenic mouse expression of IgH heavy chains comprising endogenous mouse variable regions is reduced or prevented; wherein said mouse comprises IgH-VDJC.mu. transcripts encoding said chimeric IgM polypeptide and wherein said IgM comprises human CDR-H3, and said IgH-VDJC.mu. transcripts comprise transcripts encoding human variable region CDR-H3 lengths of 19 to 22 amino acids, wherein the mean frequency of said transcripts encoding CDR-H3 lengths selected from the group consisting of 18 and 19 amino acids present in said IgH-VDJC.mu. transcripts of said mouse is between 5% and 10%. 2. The transgenic mouse of claim 1, wherein said human intronic DNA is contiguous with said mouse intronic DNA at a human DNA/mouse DNA joinder point and wherein said one or more human JH gene segments comprises a 3'-most JH gene segment contiguous with said human intronic DNA, wherein said 3'-most JH gene segment is less than 2 kb upstream of said joinder point. 3. The transgenic mouse of claim 2, wherein said 3'-most JH gene segment is less than 1 kb upstream of said joinder point. 4. The transgenic mouse of claim 2, wherein said 3'-most JH gene segment comprises a human JH6 gene segment. 5. The transgenic mouse of claim 2, wherein DNA between said joinder point and said enhancer comprises mouse JC intronic DNA, and wherein said mouse JC intronic DNA comprises less than the complete mouse JC intron. 6. The transgenic mouse of claim 2, wherein DNA between said joinder point and said enhancer comprises mouse 129 strain DNA. 7. The transgenic mouse of claim 1, wherein said genome comprises all or part of mouse heavy chain variable region inverted with respect to said heavy chain constant region to render expression of Ig heavy chains comprising a mouse variable region reduced or prevented. 8. The transgenic mouse of claim 1, wherein said genome comprises all or part of mouse heavy chain variable region away from said heavy chain constant region to render expression of Ig heavy chains comprising a mouse variable region reduced or prevented. 9. The transgenic mouse of claim 1, wherein all or part of the mouse heavy chain variable region is absent in said genome to render expression of Ig heavy chains comprising a mouse variable region reduced or prevented. 10. The transgenic mouse of claim 1, wherein said mouse is functional to produce antibody isotypes IgM and IgG specific for an antigen, said antibody isotype heavy chain comprising a human heavy chain variable region. 11. The transgenic mouse of claim 1, wherein said IgH-VDJC.mu. transcripts encoding a human variable region comprise a CDR-H3 length of 14-19 amino acids. 12. The transgenic mouse of claim 11, wherein the frequency of transcripts encoding a CDR-H3 length of 19 amino acids in said IgH-VDJC.mu. transcripts of said mouse is 5%. 13. The transgenic mouse of claim 11, wherein the frequency of transcripts encoding a CDR-H3 length of 19 amino acids in said IgH-VDJC.mu. transcripts of said mouse is less than transcripts encoding a CDR-H3 length of 17 amino acids and more than transcripts encoding a CDR-H3 length of 20 amino acids. 14. The transgenic mouse of claim 11, wherein the frequency of transcripts encoding a CDR-H3 length of 19 amino acids in said IgH-VDJC.mu. transcripts of said mouse is less than transcripts encoding a CDR-H3 length of 17 amino acids. 15. The transgenic mouse of claim 11, wherein the mean frequency of transcripts encoding CDR-H3 lengths between 14-19 amino acids in said IgH-VDJC.mu. transcripts of said mouse is between 5% and 10%.

Details for Patent 9,504,236

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-07-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-07-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-07-08